Latest studies
- CompletedPhase III
A study comparing talquetamab in combination with daratumumab or in combination with daratumumab and pomalidomide versus daratumumab in combination with pomalidomide and dexamethasone in participants with multiple myeloma that returns after treatment or is resistant to treatment
This study tests whether a new medicine called talquetamab, given alongside other cancer drugs, helps people with multiple myeloma that has returned or stopped responding to past treatments. Researchers want to see if these new combinations keep the cancer under control for longer than the current standard treatment.
Relapsed or refractory multiple myelomaJapan - CompletedPhase III
A randomized, open-label phase 3 study of amivantamab + FOLFIRI versus cetuximab/bevacizumab + FOLFIRI in participants with KRAS/NRAS and BRAF wildtype recurrent, unresectable or metastatic colorectal cancer who have received prior chemotherapy
This clinical trial is testing a new targeted drug, amivantamab, combined with chemotherapy for people with advanced bowel cancer. Researchers want to see if this combination works better at slowing cancer growth and helping people live longer than current standard targeted treatments after their first chemotherapy has stopped working.
Recurrent, unresectable or metastatic colorectal cancerJapan - RecruitingPHASE2, PHASE3
A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan in Combination With Fluorouracil, Folinic Acid, and Oxaliplatin (FOLFOX) Compared to Standard of Care in Adult Participants With First-Line Metastatic Pancreatic Ductal Adenocarcinoma
This study looks at a new drug, telisotuzumab adizutecan, combined with standard chemotherapy (FOLFOX) for advanced pancreatic cancer. It compares this combination to the usual treatment to see if it works better and is safe for adults.
Metastatic Pancreatic Ductal AdenocarcinomaPDACJapan - RecruitingPHASE2, PHASE3
A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue
This study looks at a new medicine called ponsegromab for advanced pancreatic cancer that has spread, especially when patients have lost a lot of weight and feel very tired. It aims to see if adding ponsegromab to standard chemotherapy helps more than chemotherapy alone.
CachexiaMetastatic Pancreatic Ductal AdenocarcinomaJapan - RecruitingPHASE3
A Phase III Study to Investigate the Efficacy and Safety of the Combination of Elecoglipron and Dapagliflozin in Adults With Type 2 Diabetes Mellitus
This study looks at new ways to treat type 2 diabetes by testing two medicines, Elecoglipron and Dapagliflozin, both on their own and together. Researchers want to see how well they work and if they are safe for adults with type 2 diabetes.
Type 2 Diabetes MellitusJapan - RecruitingPHASE3
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes
This study looks at a new medicine called enicepatide for people who are overweight or have obesity and also have type 2 diabetes. We want to see if it helps with weight loss and if it's safe to use.
Obesity or OverweightType 2 Diabetes MellitusJapan - RecruitingPHASE3
A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus and Impaired Renal Function on Background Dapagliflozin
This study is testing a new medicine, Elecoglipron, for adults with type 2 diabetes and kidney problems. It compares Elecoglipron to a dummy pill (placebo) to see if it's safe and effective when taken with other usual diabetes medicines, including dapagliflozin.
Type 2 Diabetes MellitusType 2 Diabetes With Chronic Kidney DiseaseJapan - RecruitingPHASE3
A Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide, a Medicine Already Used to Treat Type 2 Diabetes Mellitus
This study compares a new medicine, Elecoglipron, to an existing one, Semaglutide, for adults with Type 2 Diabetes. It aims to see if the new drug is safe and effective for people whose diabetes isn't well-controlled and who have a higher risk of heart problems.
Type 2 Diabetes MellitusJapan - RecruitingPHASE3
A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)
This study, called DLLEVATE, is looking at a new treatment, ZL-1310, for people with small cell lung cancer that has come back. It compares ZL-1310 to other standard treatments to see if it's safe and works well. You might be eligible if you're over 18 and have had previous treatments.
Small-cell Lung CancerJapan - RecruitingPHASE3
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes
This study is testing a new medicine, enicepatide, for people who are overweight or have obesity but do not have type 2 diabetes. It aims to see if the medicine helps with weight loss and if it's safe compared to a dummy medicine.
Obesity or OverweightJapan - RecruitingPHASE3
A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib
This study looks at a new drug, elritercept, for people with myelofibrosis and anaemia who are already taking ruxolitinib. It compares elritercept to a dummy drug (placebo) to see if it improves anaemia and other symptoms, and how safe it is.
MyelofibrosisAnemiaJapan - RecruitingPHASE3
INTREPID: A Study of Sapablursen Evaluating the Safety and Efficacy in Participants With Polycythemia Vera (PV)
This study is testing a new medicine called sapablursen for people with Polycythemia Vera (PV). It aims to see if adding sapablursen to usual treatment is safe and helps control the condition better. Participants will be involved for up to three years, comparing the new medicine to a dummy treatment.
Polycythemia VeraJapan - Recruiting
Quality of Pediatric Resuscitation in a Multicenter Collaborative
This study looks at how the quality of CPR given to children during a cardiac arrest affects their recovery. Researchers are observing children in hospitals to see if better CPR techniques and after-care improve survival and brain function.
Cardiac ArrestCardiopulmonary ArrestJapan - RecruitingPHASE2
Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)
This study is testing a new medicine called belzutifan for certain types of advanced cancers, including rare adrenal gland, gut, and kidney cancers. We want to see how well it works and if it's safe for people aged 12 and over.
Pheochromocytoma/ParagangliomaPancreatic Neuroendocrine TumorVon Hippel-Lindau DiseaseAdvanced Gastrointestinal Stromal TumorJapan - RecruitingPHASE3
An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.
This study looks at a new treatment called AAA617 for men with early-stage prostate cancer that has spread a little (oligometastatic). It compares AAA617 to careful watching, to see if it can stop the cancer from growing and help men live better for longer.
Oligometastatic Prostate Cancer (OMPC)Japan - RecruitingPhase III
Phase 3, randomised, double-blind, placebo- controlled, 3-arm study to investigate the safety and efficacy of efimosfermin alfa in participants with biopsy-confirmed F2- or F3-stage metabolic dysfunction-associated steatohepatitis (MASH) (ZENITH-1)
This clinical trial is testing a new injection called efimosfermin alfa for people with metabolic dysfunction-associated steatohepatitis (MASH), an inflamed fatty liver condition. Researchers want to see if monthly injections over four years can safely reduce liver fat, ease inflammation, and improve liver scarring compared to a dummy treatment.
Medical condition: Metabolic Dysfunction-Associated Steatohepatitis (MASH) Medical condition in lay language: Metabolic Fatty Liver Inflamation Therapeutic areas: Diseases [C] - Nutritional and Metabolic Diseases [C18]Japan - RecruitingPhase III
A study of JNJ-78934804 in participants with moderately to severely active Crohn's disease
This clinical trial is testing a new combination medicine, JNJ-78934804, for moderate to severe Crohn’s disease. It combines two drugs into one injection to target gut inflammation. Researchers want to see if this two-in-one approach works better than a single medicine for people whose previous treatments have stopped working.
Crohn’s diseaseJapan - Not yet recruiting
Phase 3a and 3b update of the gastric cancer module, EORTC QLQ-STO22
Researchers are updating a widely used questionnaire that measures how stomach cancer and modern treatments affect daily life and well-being. If you have stomach cancer, you can help by completing the draft survey and sharing your feedback during a single, one-off chat lasting up to an hour.
Gastric adenocarcinomaJapan - Active not recruitingPHASE3
Study to Assess the Safety and Efficacy of Viltolarsen in Ambulant Boys With DMD (RACER53-X)
This study is testing a medicine called viltolarsen for boys with Duchenne muscular dystrophy who can still walk. It is an extension study for children who already completed an earlier trial. Every participant receives the medicine through a weekly drip for nearly two years to check its safety and long-term effects.
Duchenne Muscular DystrophyJapan - RecruitingPHASE3
An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC
This study is looking at new treatments for a type of bladder cancer that has a high chance of coming back after surgery. It compares two new drugs, Dato-DXd and Rilvegostomig, with standard treatments to see if they are safer and more effective.
High-risk Muscle Invasive Urothelial CarcinomaJapan - RecruitingPHASE3
Phase 3 Trial of Reltodecacog Alfa (VMX-C001) vs Usual Pharmacological Care in Patients Taking a FXa Direct Oral Anticoagulant Who Require Urgent Surgery With or Without Heparin.
This study looks at a new medicine, VMX-C001, for people taking blood thinners (FXa DOACs) who need urgent surgery. The goal is to see if VMX-C001 helps stop bleeding effectively during the operation compared to usual care. Experts will check how well bleeding is controlled.
Blood Loss, SurgicalCoagulation DisorderJapan - RecruitingPHASE3
A Study to Evaluate Effect of AZD6234 as an Adjunct to Incretin-based Therapies in Adult Participants With Obesity or Overweight With Weight-related Comorbidity With or Without Type 2 Diabetes Mellitus
This study is testing a new medicine called AZD6234 for adults who are overweight or have obesity and other health issues, including some with type 2 diabetes. It aims to see if adding AZD6234 to their current weight management medicines helps them lose more weight safely.
Obesity or OverweightWeight-Related ComorbidityWith/Without Diabetes Mellitus, Type 2Japan - RecruitingPHASE3
A Study of Brenipatide (LY3537031) in Adult Participants With Major Depressive Disorder
This study is looking at a new medication called Brenipatide for adults with major depression. It aims to see if this new treatment, when added to usual care, can help prevent depression symptoms from coming back compared to a dummy treatment (placebo) plus usual care.
Depressive Disorder, MajorJapan - RecruitingPHASE3
A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes
This study is looking into a new medication called Eloralintide for people who are overweight or have obesity but don't have type 2 diabetes. It aims to see how well it works and if it's safe to help with weight management.
ObesityOverweightJapan - RecruitingPHASE3
A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer
This study is testing a new drug (INCA33890) alongside standard chemotherapy and another medicine (bevacizumab) for advanced bowel cancer that has spread. It aims to see if adding INCA33890 is safe and helps people live longer and feel better.
CRC (Colorectal Cancer)Japan - RecruitingPHASE3
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
This study compares two treatments for advanced left-sided bowel cancer that hasn't spread. It looks at how long people stay disease-free when given a new drug called amivantamab with chemotherapy, versus a standard drug called cetuximab with chemotherapy.
Colorectal NeoplasmsJapan - RecruitingPHASE3
Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer
This study is testing a new drug called Zanidatamab for people with advanced HER2-positive biliary tract cancer. It compares this new drug combined with standard treatments to standard treatments alone, to see if it's more effective and safe.
Biliary Tract CancerJapan - RecruitingPHASE3
A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)
This study looks at a new medicine for agitation in people with Alzheimer's. It aims to see if an experimental drug, given as capsules, is safe and works well over a long time for those who've been in similar studies before.
Alzheimer DiseaseAgitationJapan - Active not recruitingPHASE3
A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With Clinical ASCVD or at Risk for a First ASCVD Event
This study looks at a new drug, AZD0780, for people with heart disease or who are at risk of it, and who have high 'bad' cholesterol (LDL-C). We want to see if AZD0780 safely lowers this cholesterol.
Cardiovascular DiseaseJapan - Active not recruitingPHASE3
A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough
This study is testing a new medicine, BLU-5937, for adults in the UK with a long-lasting cough that hasn't responded to other treatments. It aims to see if the medicine can reduce how often people cough over 24 weeks, compared to a dummy pill.
CoughRefractory Chronic CoughJapan - Active not recruitingPHASE1, PHASE2
A Study of Amivantamab and Capmatinib Combination Therapy in Unresectable Metastatic Non-small Cell Lung Cancer
This study is looking at a new way to treat a type of lung cancer called non-small cell lung cancer. It combines two medicines, amivantamab and capmatinib, to see how well they work together and what the best dose is.
Carcinoma, Non-Small-Cell LungJapan - Active not recruitingPHASE2
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease
This study is looking at a new combination treatment, JNJ-78934804, for people aged 18-65 with Crohn's disease that is moderate to severe. It compares this new treatment to existing medicines, guselkumab and golimumab, to see how well it works over 48 weeks.
Crohn's DiseaseJapan - RecruitingPHASE3
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
This study compares two treatments for multiple myeloma that has come back or not responded to previous treatments. It looks at a new drug, mezigdomide, combined with standard medicines (bortezomib and dexamethasone), against another combination (pomalidomide, bortezomib, and dexamethasone). The aim is to see which combination is more effective and safe.
Relapsed or Refractory Multiple MyelomaJapan - RecruitingPHASE1, PHASE2
A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
This study is looking at a new drug called repotrectinib for advanced cancers that have specific gene changes (ALK, ROS1, or NTRK). It aims to find the best dose and see how well it works in shrinking tumours and how safe it is.
Locally Advanced Solid TumorsMetastatic Solid TumorsJapan - Recruiting
Pompe Disease Registry Protocol
This registry tracks people with Pompe disease globally. It helps us understand the condition better, how it changes over time, and the effects of treatments. The goal is to improve care for everyone with Pompe disease.
Glycogen Storage Disease Type IIPompe DiseaseJapan - RecruitingPHASE3
A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma
This study is testing a new drug, linvoseltamab, for multiple myeloma that has returned or needs re-treatment. It compares linvoseltamab to a standard three-drug combination (elotuzumab, pomalidomide, and dexamethasone) to see which works better and has fewer side effects.
Relapsed Refractory Multiple Myeloma (RRMM)Japan - RecruitingPHASE3
BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease
This study looks at a new medicine called BGB-43395 combined with letrozole for advanced breast cancer. It compares this new combination to standard treatments (other CDK4/6 inhibitors plus letrozole) for people who haven't had previous treatment for their advanced cancer.
HR+/HER2- Breast CancerJapan - Active not recruitingPHASE3
A Clinical Study of Intismeran Autogene (V940) Plus Pembrolizumab in People With High-Risk Melanoma (V940-001)
This study looks at a new personalised treatment, Intismeran Autogene, combined with Pembrolizumab for high-risk melanoma. It aims to see if this combination can stop cancer from coming back better than Pembrolizumab alone after surgery, focusing on safety and effectiveness.
MelanomaJapan - Enrolling by invitationPHASE3
Selatogrel Outcome Study in Suspected Acute Myocardial Infarction
This study looks at a new treatment called Selatogrel for people who have recently had a heart attack and are at risk of another. It checks if taking Selatogrel when symptoms start can help prevent a second heart attack.
Acute Myocardial InfarctionJapan - Active not recruitingPHASE3
A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
This study looks at new treatments for a type of lung cancer where standard treatment has stopped working. It compares a drug called Dato-DXd, alone or with osimertinib, against usual chemotherapy to see which helps patients live longer without their cancer getting worse.
Metastatic Non-small Cell Lung CancerJapan - Active not recruitingPHASE2
Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer
This study is looking at new ways to treat advanced liver and bile duct cancers. It tests new medicines, called immunomodulators, either on their own or alongside other cancer drugs, to see how well they work and if they are safe.
Hepatocellular CarcinomaBiliary Tract CancerJapan - Active not recruitingPHASE3
Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)
This study is looking at a new medicine called ravulizumab for adults with a kidney condition called IgAN. We want to see if it helps reduce kidney damage and improve kidney function compared to a dummy medicine.
Immunoglobulin A NephropathyIgANJapan - Active not recruitingPHASE3
Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)
This study looks at a new drug, pembrolizumab, for early-stage breast cancer. It's for people with a specific type of breast cancer (ER+/HER2-). Researchers want to see if adding pembrolizumab to standard chemotherapy and hormone therapy works better than standard treatment alone.
Breast CancerJapan - Active not recruitingPHASE3
Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)
This study looks at a new drug, trastuzumab deruxtecan, for people in the UK with HER2-positive stomach or food pipe cancer. It compares this drug to standard treatments for patients whose cancer has grown despite previous therapy. The aim is to see if the new drug works better and is safe.
Gastric Cancer, AdenocarcinomaGastroesophageal Junction AdenocarcinomaJapan - RecruitingPHASE3
A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
This study compares a new medicine called nemtabrutinib with existing treatments (ibrutinib or acalabrutinib) for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who haven't had treatment before. The aim is to see if the new drug is as good or better.
Chronic Lymphocytic LeukemiaSmall Lymphocytic LymphomaJapan - Active not recruitingPHASE3
A Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)
This study compares a new medicine called epcoritamab with standard chemotherapy for a type of lymphoma (DLBCL) that hasn't responded to earlier treatments. It aims to see if epcoritamab is safer and more effective for patients who can't have or have already had a stem cell transplant.
Diffuse Large B-cell LymphomaJapan - RecruitingPHASE2, PHASE3
A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
This study looks at a new drug, Navlimetostat, combined with standard treatments for advanced lung cancer. It compares this combination to standard treatments alone in patients whose cancer has a specific genetic change called an MTAP deletion. The aim is to see if the new combination works better.
Metastatic Non-small Cell Lung Cancer With MTAP DeletionJapan - RecruitingPHASE3
A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)
This study is testing new treatments for a type of lung cancer called non-small cell lung cancer. Researchers want to see if a combination of two medicines, calderasib and pembrolizumab, works better than pembrolizumab with chemotherapy to slow down cancer growth.
Non-small Cell Lung CancerJapan - Active not recruitingPHASE3
A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma
This study compares a new combination treatment, teclistamab with daratumumab (Tec-Dara), against standard treatments for multiple myeloma that has come back or isn't responding well. It aims to see if the new combination works better.
Multiple MyelomaJapan - Active not recruitingPHASE3
A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced or Metastatic Non-small Cell Lung Cancer
This study is comparing two ways of giving a medicine called amivantamab for advanced lung cancer. One is through a drip, and the other is a new injection under the skin. We want to see if the injection is easier and quicker for patients.
Advanced or Metastatic Non-small Cell Lung CancerJapan